Canagliflozin: all 123 studies that test it
Page 1 of 2. Open to participants first (12), then studies with results posted, then the rest; newest registration first within each.
- Canagliflozin Plus Progestin for Atypical Endometrial Hyperplasia and Early-Stage Endometrial CancerNot yet recruitingNCT07890064Phase 2
- Efficacy and Safety of Canagliflozin in the Treatment of Type 2 Diabetes With Mild Cognitive ImpairmentRecruitingNCT07711171Phase 4
- Safety and Efficacy of Canagliflozin in Patients With Locally Advanced or Advanced Solid CancerRecruitingNCT07703163Phase 1
- Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)Enrolling by invitationNCT07547878Phase 4
- CANagliflozin In DIALysis PatientsNot yet recruitingNCT07527390Phase 4
- Safety and Efficacy of Canagliflozin in Patients With Metastatic High Microsatellite Instability (MSI-H) Colorectal CancerRecruitingNCT07076823Phase 1
- SGLT2 Inhibitor Utilization Re-perfusion TherapyNot yet recruitingNCT06858436Phase 4
- The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney DiseaseRecruitingNCT06528405Phase 2
- Efficacy of Canagliflozin Versus Metformin in Women With Polycystic Ovary SyndromeNot yet recruitingNCT06256289Phase 4
- Canagliflozin in Advanced Renal Disease With MRI EndpointsRecruitingNCT06182839Phase 2
- Canagliflozin With Gemcitabine in Pancreatic CarcinomaNot yet recruitingNCT05903703Not applicable
- Canagliflozin Targeting Vascular InflammationRecruitingNCT05427084Phase 2/3
- A Study to Assess Safety of Canagliflozin and Metformin Hydrochloride Combination Given as a Supplement to Diet and Exercise to Improve Blood Sugar Level in Indian Adult Participants With DiabetesCompletedNCT04288778Phase 4Results posted
- A Study on Impact of Canagliflozin on Health Status, Quality of Life, and Functional Status in Heart FailureCompletedNCT04252287Phase 3Results posted
- Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic NephropathyCompletedNCT03436693Phase 3Results posted
- An Efficacy Study of Canagliflozin or Sitagliptin to Determine Glucose Variability in Mexican Participants With Type 2 Diabetes Mellitus Inadequately Controlled on MetforminCompletedNCT03267576Phase 4Results posted
- A Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (>=10 to <18 Years) With Type 2 Diabetes MellitusCompletedNCT03170518Phase 3Results posted
- Role of Canagliflozin on CD34+ Cells in Patients With Type 2 DiabetesCompletedNCT02964585Phase 4Results posted
- Treatment of Diabetes in Patients With Systolic Heart FailureCompletedNCT02920918Phase 4Results posted
- CARAT: Canagliflozin vs. Placebo for Post Bariatric Patients With Persistent Type 2 DiabetesTerminatedNCT02912455Phase 4Results posted
- Effect of Canagliflozin in T1DM (Type 1 Diabetes Melitus) After Interruption of Continuous Subcutaneous Insulin InfusionCompletedNCT02673138Not applicableResults posted
- Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes MellitusCompletedNCT02622113Phase 4Results posted
- Pharmacogenetics of SGLT2 InhibitorsTerminatedNCT02462421Phase 4Results posted
- Mechanisms of Weight Loss With SGLT2 InhibitionCompletedNCT02360774Phase 4Results posted
- Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin)CompletedNCT02354235Phase 3Results posted
- Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic PatientsCompletedNCT02324842Not applicableResults posted
- Effects of Co-administration of Canagliflozin 300 mg and Phentermine 15 mg With Placebo in the Treatment of Non-Diabetic Overweight and Obese ParticipantsCompletedNCT02243202Phase 2Results posted
- Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With GLP-1 Analogue in Patients With Type 2 Diabetes MellitusCompletedNCT02227849Phase 4Results posted
- Efficacy and Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes MellitusCompletedNCT02220920Phase 4Results posted
- Long-Term Safety Study of MT-2412 in Japanese Patients With Type 2 DiabetesCompletedNCT02220907Phase 3Results posted
- A Study of Effects of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Participants With Type 1 Diabetes Mellitus (T1DM)CompletedNCT02139943Phase 2Results posted
- Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic NephropathyCompletedNCT02065791Phase 3Results posted
- A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and SitagliptinCompletedNCT02025907Phase 4Results posted
- A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes MellitusCompletedNCT01989754Phase 4Results posted
- Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive AgentsCompletedNCT01939496Phase 4Results posted
- A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and ExerciseCompletedNCT01809327Phase 3Results posted
- A Study to Evaluate the PK/PD and Safety of TA-7284 in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal ImpairmentCompletedNCT01512849Phase 1Results posted
- Efficacy and Safety Study of TA-7284 in Patients With Type 2 DiabetesCompletedNCT01413204Phase 3Results posted
- Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes MellitusCompletedNCT01387737Phase 3Results posted
- A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a SulphonylureaCompletedNCT01381900Phase 3Results posted
- An Efficacy, Safety, and Tolerability Study of Canagliflozin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin MonotherapyCompletedNCT01340664Phase 2Results posted
- The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial)CompletedNCT01137812Phase 3Results posted
- The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)CompletedNCT01106690Phase 3Results posted
- The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)CompletedNCT01106677Phase 3Results posted
- A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes MellitusCompletedNCT01106651Phase 3Results posted
- The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea)CompletedNCT01106625Phase 3Results posted
- The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) TrialCompletedNCT01081834Phase 3Results posted
- An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal ImpairmentCompletedNCT01064414Phase 3Results posted
- CANVAS - CANagliflozin cardioVascular Assessment StudyCompletedNCT01032629Phase 3Results posted
- An Efficacy, Safety, and Tolerability Study for TA-7284 in Patients With Type 2 DiabetesCompletedNCT01022112Phase 2Results posted
- CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus GlimepirideCompletedNCT00968812Phase 3Results posted
- Safety, Pharmacokinetics and Pharmacodynamics of TA-7284 in Type 2 Diabetic PatientsCompletedNCT00707954Phase 1/2Results posted
- A Study of the Safety and Effectiveness of Canagliflozin (JNJ-28431754) in Promoting Weight Loss in Overweight and Obese Patients Who do Not Have DiabetesCompletedNCT00650806Phase 2Results posted
- An Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 DiabetesCompletedNCT00642278Phase 2Results posted
- Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.CompletedNCT06851962Phase 4
- The Efficacy and Tolerability of Canagliflozin in Healthy IndividualCompletedNCT06301529Phase 4
- SGLT-2 Inhibitor Effects on Cardiac and Hepatic Metabolic Profiles for the Diabetes Patients Combined With ObesityCompletedNCT05764811Not applicable
- Renal Mechanism of SGLT2 InhibitionActive, not recruitingNCT05507892Phase 2
- Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver DiseaseStatus unknownNCT05422092Not applicable
- Canagliflozin and Myocardial FibrosisCompletedNCT05367063Phase 4
- Canagliflozin in Patients With Acute Decompansted Heart FailureCompletedNCT05364190Phase 3
- Safety and Efficacy of Canagliflozin in Advanced CKDCompletedNCT05309785Phase 4
- Intervention Effect of Canagliflozin on Prediabetes in Patients With HIV.Status unknownNCT05135039Not applicable
- GliflOzin in eLderly Diabetic patiENts: A praGmatic Intraclass Evaluation TrialStatus unknownNCT04796428Phase 4
- Canagliflozin in Postprandial Hyperinsulinemic Hypoglycemia (CANA-PHH-RYGB)Status unknownNCT04720859Not applicable
- Effects of SGLT2i on the Cognitive Function in T2DM Patient (ESCDP)CompletedNCT04304261Phase 3
- A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid TumorsStatus unknownNCT04073680Phase 1/2
- Effects of SGLT2 Inhibitors on Islet Cell Function and Insulin Sensitivity in Patients of Type 2 Diabetes MellitusStatus unknownNCT04014192Phase 4
- Glucose Absorption and Gut Hormone Secretion After Gastric BypassStatus unknownNCT03426956Not applicable
- Impact of a Short-term Treatment With Canagliflozin (Canacardia-HF)WithdrawnNCT03298009Not applicable
- Effects of Canagliflozin on Intravascular Volume and HemodynamicsWithdrawnNCT03190798Phase 4
- Genetics of Response to CanagliflozinActive, not recruitingNCT02891954Phase 1
- A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted ParticipantsCompletedNCT02865668Phase 1
- A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin Extended Release Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted ParticipantsCompletedNCT02851212Phase 1
- A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release (XR) With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted ParticipantsCompletedNCT02851095Phase 1
- A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted ParticipantsCompletedNCT02846506Phase 1
- Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen for T2DM During RamadanCompletedNCT02694263Phase 4
- TriMaster: Study of a DPP4 Inhibitor, SGLT2 Inhibitor and Thiazolidinedione as Third Line Therapy in Patients With Type 2 Diabetes.CompletedNCT02653209Phase 4
- Canagliflozin-Mealtime Insulin RescueStatus unknownNCT02624908Phase 4
- The Effect of add-on Canagliflozin in Patients With Type 2 Diabetes Treated With U-500 InsulinWithdrawnNCT02597309Phase 4
- Acute Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor on Bone Metabolism in Healthy VolunteersCompletedNCT02404870Phase 1
- Bioequivalence Study of Metformin Component of Fixed Dose Combination (FDC) Immediate Release (IR) Tablet of Canagliflozin and Metformin Compared to Metformin IR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted ParticipantsCompletedNCT02221180Phase 1
- Bioequivalence Study of Metformin Component of Canagliflozin and Metformin Fixed Dose Combination Immediate Release (IR) Tablet Comparing With Metformin IR Tablet Co-administered With Canagliflozin Tablet in Healthy Fed and Fasted ParticipantsCompletedNCT02220218Phase 1
- Glycemic Durability After Metformin FailureStatus unknownNCT02142309Phase 4
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed ParticipantsCompletedNCT02077803Phase 1
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual ComponentsCompletedNCT02073227Phase 1
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed ParticipantsCompletedNCT02071368Phase 1
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual ComponentsCompletedNCT02065752Phase 1
- Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)CompletedNCT02009488Phase 1
- A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes MellitusCompletedNCT02000700Phase 1
- Study to Evaluate the Effect of Single Doses of LX4211 and Canagliflozin on Intestinal Glucose Absorption in Healthy Adult SubjectsCompletedNCT01916863Phase 1
- A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics, Pharmacodynamics, and Safety of Simvastatin in Healthy VolunteersCompletedNCT01821027Phase 1
- A Study to Assess Electrocardiogram Results in Healthy Volunteers Receiving Canagliflozin (JNJ-28431754)CompletedNCT01787357Phase 1
- A Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Volunteers With Varying Degrees of Kidney FunctionCompletedNCT01759576Phase 1
- A Study to Investigate Whether Pharmacokinetic and Pharmacodynamic Interactions Exist Between Metformin and Canagliflozin (JNJ-28431754) in Healthy VolunteersCompletedNCT01756417Phase 1
- Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Otherwise Healthy Obese VolunteersCompletedNCT01756404Phase 1
- A Study to Assess the Pharmacokinetics and Pharmacodynamics of Canagliflozin (JNJ-28431754) in Healthy Indian VolunteersCompletedNCT01748526Phase 1
- A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics, Pharmacodynamics, and Safety of Glyburide in Healthy VolunteersCompletedNCT01733108Phase 1
- A Study to Assess the Effects of Cyclosporine on the Pharmacokinetics and Safety of Canagliflozin (JNJ-28431754) in Healthy VolunteersCompletedNCT01718652Phase 1
- A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics and Safety of Digoxin in Healthy Volunteers.CompletedNCT01714206Phase 1